EGAGenomicsIllumina HiSeq 2000;, Illumina HiSeq 2500;https://ega-archive.org/datasets/EGAD0000100132113EGA dataset EGAD00001001321EGA<h4>Background</h4>Anaplastic thyroid carcinoma is the most undifferentiated form of thyroid cancer and one of the deadliest of all adult solid malignancies. Here we report the first genomic and transcriptomic profile of anaplastic thyroid cancer including those of several unique cell lines and outline novel potential drivers of malignancy and targets of therapy.<h4>Methods</h4>We describe whole genomic and transcriptomic profiles of 1 primary anaplastic thyroid tumor and 3 authenticated cell lines. Those profiles augmented by the transcriptomes of 4 additional and unique cell lines were compared to 58 pairs of papillary thyroid carcinoma and matched normal tissue transcriptomes from The Cancer Genome Atlas study.<h4>Results</h4>The most prevalent mutations were those of TP53 and BRAF; repeated alterations of the epigenetic machinery such as frame-shift deletions of HDAC10 and EP300, loss of SMARCA2 and fusions of MECP2, BCL11A and SS18 were observed. Sequence data displayed aneuploidy and large regions of copy loss and gain in all genomes. Common regions of gain were however evident encompassing chromosomes 5p and 20q. We found novel anaplastic gene fusions including MKRN1-BRAF, FGFR2-OGDH and SS18-SLC5A11, all expressed in-frame fusions involving a known proto-oncogene. Comparison of the anaplastic thyroid cancer expression datasets with the papillary thyroid cancer and normal thyroid tissue transcriptomes suggested several known drug targets such as FGFRs, VEGFRs, KIT and RET to have lower expression levels in anaplastic specimens compared with both papillary thyroid cancers and normal tissues, confirming the observed lack of response to therapies targeting these pathways. Further integrative data analysis identified the mTOR signaling pathway as a potential therapeutic target in this disease.<h4>Conclusions</h4>Anaplastic thyroid carcinoma possessed heterogeneous and unique profiles revealing the significance of detailed molecular profiling of individual tumors and the treatment of each as a unique entity; the cell line sequence data promises to facilitate the more accurate and intentional drug screening studies for anaplastic thyroid cancer.The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.Kasaian Katayoon K, Wiseman Sam M SM, Walker Blair A BA, Schein Jacqueline E JE, Zhao Yongjun Y, Hirst Martin M, Moore Richard A RA, Mungall Andrew J AJ, Marra Marco A MA, Jones Steven J M SJCarcinomas, Anaplastic., Carcinoma, THAP, Anaplastic Thyroid Cancer, Transcriptome, Anaplastic Thyroid, determination, thyroid cancer, Transcriptome Profile, Profile, Expression Profiles, thyroid carcinoma, Gene Expression Profile, anaplastic, Gene, Anaplastic Thyroid Carcinoma, whole genome, Profiles, Cancers, Signatures, Anaplastic, Thyroid Cancers, Gene Expression, Thyroid Carcinomas, Expression Signature, Gene Expression Profiles, Expression Signatures, Gene Expression Signatures, chemical analysis, Anaplastic Thyroid Cancers, Transcriptomes, Anaplastic Thyroid Carcinomas, Gene Expression Signature, assay, Thyroid Cancer, Signature, Expression Profile, Transcriptome Profiles, CancerCarcinomas, Thyroid Cancers, treatment, Therapy, Carcinoma, THAP, disease management., Anaplastic Thyroid Cancer, Anaplastic Thyroid, Thyroid Carcinomas, Therapeutic, thyroid cancer, Anaplastic Thyroid Cancers, Anaplastic Thyroid Carcinomas, Therapies, thyroid carcinoma, anaplastic, Treatment, Anaplastic Thyroid Carcinoma, Thyroid Cancer, Cancers, Treatments, Anaplastic, CancerF10A12.20, l(1)Ab, CG11489, Act5c, l(1)G0010, Dlats, X-linked, 2410041A17Rik, RPD3, ACTG, ACTE, Neoplasms, Lats/Warts, mental retardation, Benign Neoplasm, ACT5C, CG12051, WTS, Wts, DmelCG11489, fs(1)M34, Serpin A3, Tumor, Malignant, Bach, csp2, Act5, l(1)G0420, Srpk79D, DmelCG12051, l(1)G0025, syndromic 6 (formerly), Line, HEL-176, CG4601, Cell growth-inhibiting gene 24|25 protein, l(3)100Aa, wts, TELO1, intellectual disability, Wilson Turner mental retardation syndrome (formerly), A, C, act5C, cyt5C, X-linked intellectual disability - gynecomastia - obesity, CK01209, Malignancy, DHO, BRWS2, CG18572, CG12072, CDLS5, AT1, WTS/LATS, DmelCG12072, fs(1)829, Neoplasias, Act42a, anon-EST:fe2D2, 1700027G07Rik, act 42A, DmelCG18572, ATA, SRPK1, Ac5C, ATC, CG4027, ATD, ATE, ACT, Act, Malignancies, dmLATS, T11, Act-5C, Cte-II, Cancer, Tumors, l(1)G0177, WGS, with gynecomastia and obesity (formerly), 42A, lats, centroradialis, CPS, l(1)G0330, Malignant Neoplasm, Data Set, Actin/BAP47, CTE-II, AACT, atc, dJ393D12.2, Cell Lines, CTE-IIa, MENE (3R)-G, act, Ach1, hBACH, ACH1, LATS, LACH1, Cell, act42A, GIG25, Benign, CAD, Wilson-TURNER X-linked mental retardation syndrome, Su(b), Alpha-1-antichymotrypsin His-Pro-less, beta-actin, BEST:CK01209, AFFX-Dros-ACTIN_M_r_at, GIG24, WARTS, M32055, Warts, Neoplasm, TEL1, DFNA26, Act42, actin, MRXS6, ACTA3, LACH, HDACL1, wart, GAT, DFNA20, SRPK, HD8, Lines, Wilson Turner intellectual disability syndrome (formerly), l(1)G0079, DmelCG4027, PYR1, l(1)G0117, VSCM, act 5C, Benign Neoplasms, Actin, Cancers, beta-actin/Bap47, Malignant Neoplasms, l(1)G0486, l(1)G0245, Wilson-TURNER X-linked intellectual disability syndrome, actin5C, l(1)G0009, Actin5C., wts/lats, lts, ACTL3, Lach1, warts/lats, ATDC, Warts/Lats, CG9085, Lats, DRORUD, BAP47, ACTSG, other neoplasm, BACH, Bap47, Neoplasia, Wts/LatsUVO Gene Mutation, Forms, Anaplastic., Materials, H. pylori Positive, Adenomas, CT22273, mTOR Signaling Pathway PID, thyroid carcinoma, Snf2l2, Biochemical Pathway, CG18438, Tumor, papillary thyroid gland carcinoma, Hd10, ERBB2 Amplification, Nonmedullary Thyroid Carcinoma, Positive Charge, RET/PTC Rearrangement, Hepatitis C Virus RNA Positive, p53 Mutation, Reto, chromosome number anomaly, Summary Report, PGR Positive, SCO5, AA120551, SCO1, Analysis, myd, HD10, Thyroid Neoplasm, Methylated MGMT Promoter, ERA Positive, like-acetylglucosaminyltransferase, G Protein Subunit Alpha q Gene Mutation, Analyses, Adenoma, IDH Gene Mutation, CD324 Gene Mutation, D-ret, Hepatitis B Virus Core Antibody Positive, c-KIT Positive, d1401, Flavoprotein Subunit of Complex II Positive, Tissue, B7H1 Positive, BEK Gene Mutation, procedures, W, node-positive, Cadherin 1 Gene Mutation, ESTRB Positive, XH2 Gene Mutation, papillary carcinoma of the thyroid, Fgfr7, SNF2, Catenin Beta 1 Gene Mutation, BEK, ER Beta Positive, Bs, Bcl11a, Homo sapiens disease, Telomerase Reverse Transcriptase Gene Promoter Mutation, Tk1, CG4943, Papillary Thyroid, Methylated MGMT Gene Promoter, thyroid gland cancer, Tumors, screening, Human Immunodeficiency Virus Positive, KGFR Gene Rearrangement, c-erbB2 Gene Amplification, MRXSL, BB130002, B-RAF Gene Rearrangement, Anti-HBc Positive, mKIAA4192, Hepatitis B Virus Surface Antibody Positive, Estrogen Receptor Alpha Positive, Anaplastic, Shift, ret, hBRM, Benign, JWS, SDHIP Positive, HSCR1, mKIAA0609, DmelCG14396, simple tissue, FGFR-2 Gene Rearrangement, FLT2 Gene Mutation, FGFR-1 Gene Rearrangement, RET Gene Rearrangement, Carcinomas, HD-38, mTOR signaling pathway, statistical significance, pbt, NRAS Gene Mutation, Anaplastic Thyroid Cancer, Anaplastic Thyroid, EMS2, ECAD Gene Mutation, BBDS, Benign Neoplasms, i100, EST2 Promoter Mutation, Present, ESR Positive, PDCD1L1 Positive, Malignant Neoplasms, MeCp2, MDC1D, FR1, Report, Positive EBV Serum Test, enr, IDH Gene Family Mutation, Familial Nonmedullary Thyroid Cancer, Cells, N-RAS Gene Mutation, HER2/Neu Amplification, KRAS Gene Mutation, Epigenetics, Expression of PD-L1, AA473386, HD-59, SDHF Positive, Nuclear Receptor Subfamily 3 Group A Member 2 Positive, BRAHMA, i79, BRCA1-Associated Protein 1 Gene Mutation, Neoplasms, CDHE Gene Mutation, AKGDH, Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Hepatitis B Virus Surface Antigen Positive, Chromosome 20 Long Arm, CG1061, Core Genome, Screening, CEK3, G Protein Subunit Alpha 11 Gene Mutation, Technique, B7-H Positive, Cadherin-Associated Protein, In, MGMT Gene Methylation, Hepatitis B Core Antibody Positive, Profile, Accessory Genome, Target, C87398, neoplasm of thyroid gland, Ssxt, E1k, BEK Gene Rearrangement, Neoplasias, Study, RET Rearrangement, drugs, RAD54 Homolog Gene Mutation, genome, BFR-1, Molecular Signature, Thyroid Cancer, HER-2 Gene Amplification, Investigative Reports, papillary cancer of the thyroid, Including, e1k, Pharmaceuticals, New, Positive EBV Test, proto-oncogene c-Kit, findings, Malignant Neoplasm, PR Positive, Hepatitis B Surface Protein Antigen Positive, disorders, copies, BRAF1, Estrogen Receptor Positive, Dsmurf, Pangenome, DRet, c-Ret, EVI9, B-RAF1 Gene Rearrangement, dSmurf, MT, ATRX, BRAF Gene Rearrangement, mTOR Signaling Pathway BioCarta, Smurf ubiquitin ligase, Research Reports, condition, i150, Expression Positive, dRET, CDHF12, FLG Gene Mutation, PAX8 Rearrangement, Ana, Androgen Receptor Positive, HGFR Gene Amplification, ESR1 Positive, MET Gene Amplification, c-MET Gene Amplification, XKrk1, ER-Alpha Positive, Proto Oncogene, Methylated MGMT, ERG Rearrangement, Accuracy, HBsAg Positive, TERT Gene Promoter Mutation, Nonmedullary, SNF2L2, Ret Proto-Oncogene Rearrangement, 2810047E18Rik, Pan-genome, C-Kit, Braf2, Primary Cause of Death, IDH Mutation, 1p/19q Co-deletion, target lesion, SNF2LA, Expression Profiling, SDHA Positive, 20q, Q Polypeptide Gene Mutation, Dtk1, ZNF856, Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Molecular Profiling, Neoplasia, BRM, Dret, Estrogen Receptor 2 Positive, mRNA Expression, XNP Gene Mutation, O-6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation, ER Positive, v-Ets Erythroblastosis Virus E26 Oncogene Like Gene Rearrangement, CTIP1, Expression Detected, Tp53, protein expression, HRAS1 Gene Mutation, G-ALPHA-q Gene Mutation, BAP1 Gene Mutation, Techniques, DSmurf, DFGF-R2, Statistical Significance, Pharmaceutical Product, DFGF-R1, Details, HBFQTL5, v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Mutation, papillary thyroid carcinoma, TP53, Abnormal, DFR1, gene expression, RS, human disease, Estrogen Receptor Beta Positive, Thyroids, SWI2, Identification, Aneuploid, statistically significant, DOG1 Positive, anaplastic, Copies, ETV Family Gene Rearrangement, Ets Variant Family Rearrangement, FLT2 Gene Rearrangement, Ctip1, Papillary Thyroid Carcinoma, Sth1p, Rearrangement identified, Novel, FGFR3 Gene Rearrangement, DmelCG5942, ECT1 Gene Mutation, Estrogen Receptor 1 Positive, Thyroid Carcinomas, Fibroblast Growth Factor Receptor 2 Gene Mutation, Had, DFR-1, IDH Family Mutation, Pharmaceutical, CD333 Gene Rearrangement, disease management, D6Ertd631e, Sl, RET51, Has, ATRX Gene Mutation, D-smurf, ERG Gene Rearrangement, Primary Tumor, THYROID, Papillary Thyroid Cancers, gyltl1b-b, Tr-kit, HER2 Gene Mutation, Fgfr-7, Fgfr-2, results, Gene Expression, CDHR16, Hepatitis B Surface Antibody Positive, Gland, significant, SYT, HIV Positive, PRCDTH, KIT, KIAA0609, HIV positive, Lines, 1p/19q Codeletion, POSITIVE, tyrosine-protein kinase Kit, Guanine Nucleotide Binding Protein (G Protein), Yes, Epigenetic, SDH2 Positive, Detailed, Heterogeneity, AA387315, ERBB2 Gene Mutation, Methodological Study, Treatments, loss of, Lowering, data analysis, disease, head and neck cancer, E(E2F)3A, Expressed, Matched Normal, ER-Beta Positive, P53, p44, HRAS Gene Mutation, papillary cancer of thyroid gland, molecular pathway, Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation, DTRK(FR1), thyroid gland papillary cancer, AU043015, A430090G16, dSNF2, BRAF Rearrangement, CDH1 Gene Mutation, Procedures, KGFR, K-SAM, Prevalent, p53, ARABIDOPSIS THALIANA BRAHMA, SCF receptor activity, Anti-HBs Positive, c-erbB2 Gene Activation, RSTS2, Malignant, Gyltl1a, RET-ELE1, Investigative, CHA2, Fp Positive, Fibroblast Growth Factor Receptor 1 Gene Rearrangement, WBP10, OGD Gene Mutation, Genetic heterogeneity, Anti-HBcAb Positive, Studies, Mass, Hep C RNA Positive, CD274 Antigen Positive, Epithelial Gene Mutation, primary, AW548891, MET Proto-Oncogene, study, Fdc, PRESENT, Papillary Thyroid Carcinomas, SWS Gene Mutation, TAOS2 Positive, ATBRM, Outlines, ECT1, Methylguanine-DNA Methyltransferase Gene Promoter Methylation, Neuroblastoma RAS Viral Oncogene Homolog Gene Mutation, H-ras Gene Mutation, ETV Gene Rearrangement, Loss, data processing, Found, CD332 Gene Rearrangement, Ets Variant Gene Family Rearrangement, disorder, HER2 Gene Amplification, TRP53, Preparation, MKRN1, Frame Device, CTNNB Gene Mutation, progesterone receptor positive, RASH1 Gene Mutation, Possess, target_lesion, Anti-Hepatitis B Virus Core Antibody Positive, PPMX, Cell Lines, Targeted, medical condition, Papillary Carcinoma Of Thyroid, rnf61, CG14396, Xp53, NR3A2 Positive, Mass Screenings, TCGA, MGMT Gene Promoter Methylation, The Cancer Genome Atlas, Copy, TMEM16A Positive, Catenin Beta-1 Gene Mutation, MGMT Methylation, AR Positive, Lowered, c-KIT, FMS-Like Tyrosine Kinase 2 Gene Mutation, HIV Positivity, Mast/Stem Cell Growth Factor Receptor Kit Positive, FGFR-2 Gene Mutation, Calcium-Dependent Adhesion Protein, introduction, D630021H01Rik, HTL/FGFR1, Accurate, Drug, Preparations, Therapeutic, Braf-2, Data, CG7184, Treatment, HBs Antigen Positive, CD274 Molecule Positive, Summary, Duplicate, Field Report, methodology, RET9, GTPase Gene Mutation, Anti-HBsAb Positive, Beta Gene Mutation, mTOR Signaling Pathway KEGG, Product, acetylglucosaminyltransferase-like protein, AUTSX3, CFD1, MTC1, Progesterone Receptor Positive, Progress Reports, FGFBR Gene Rearrangement, aa, Mutations, DmelCG7223, KL receptor activity, cancer of thyroid, Compared, Method, bbl, Line, symptoms, Nuclear Receptor Subfamily 3 Group A Member 1 Positive, Gsfsow3, Erg-3 Gene Rearrangement, CD332 Gene Mutation, adult, Ha-ras Gene Mutation, T3F17.33, Nonmedullary Thyroid Carcinomas, Aneuploid Cell, treatment, average, EXPRESSED, NCBRS, HRas Proto-Oncogene, thyroid cancer, Progress Report, BCC7, Genomes, TRT Promoter Mutation, GAQ Gene Mutation, Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Amplification, Mbp-1, Pathways, Of Each, Comparison, FGFR1 Gene Rearrangement, PD-L1+, high grade, Epigenomic, NEU Gene Mutation, v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement, replicate, ogdc, Field Reports, Bek, FGFR3 Gene Mutation, SDHB Positive, medicine, Expression Signature, Smurf, K-RAS Mutation, Familiar, CD331 Gene Rearrangement, OGDC, C-HA-RAS1 Gene Mutation, MET Amplification, ZNF-HX Gene Mutation, ERBB2 Gene Amplification, Beta Catenin Gene Mutation, RET, mKIAA1809, Pathway, Index, BCL-11A, KAT3B, Procedure, Lack, RFP, Alpha 11 Gene Mutation, PBT, CD331 Gene Mutation, ERB Positive, Cadherin, papillary carcinoma of the thyroid gland, JKT4 Gene Rearrangement, bfy, CMC1 Gene Mutation, fg, Htl, Fr1, P53 Gene Mutation, Guanine Nucleotide-Binding Protein, PAX8 Gene Rearrangement, CG5942, NR3A1 Positive, Field, signs, INSDC_feature:gene, Keratinocyte Growth Factor Receptor Gene Rearrangement, Methodological, HER2 Amplification, MRX16, Genomic, CD333 Gene Mutation, Makorin-1, Papillary, Positive Epstein-Barr Virus Test, Mbd5, Chromosome, primary tumor, Material, FGFBR Gene Mutation, TCS1 Promoter Mutation, bhy, BFGFR Gene Mutation, krk1, Potential, HCV RNA Positive, MRX79, MEN2, LFS1, cancer of the thyroid, LARGE1, ER+, Receptor Tyrosine Kinase Gene Amplification, FGFR1 Gene Mutation, p55 Gene Rearrangement, FLG Gene Rearrangement, PDCD1LG1 Positive, disease or disorder, DmHD-59, Thyroid Glands, Frame, ETV Rearrangement, androgen receptor positive, HBs Positive, Positive Number, MDDGB6, Matched_Normal, positive test result, v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation, 1500041B07Rik, GNAQ Gene Mutation, CHR2, Thyroid Adenoma, PD-L1 Positive, Aneuploid Cells, CTNNB1 Gene Mutation, FGFR2 Gene Rearrangement, Papillary Thyroid Cancer, ANO1 Positive, D930021L15Rik, Statistically Significant, Machine-like Murmur, 2610209L14Rik, RNF61, FGFR, RAD54 Gene Mutation, Expression, Cancer of the Thyroid, Chromosome 20 Distal Arm, SSXT, Cancer, CD117 Positive, FGFR2 Gene Mutation, Products, Aneuploids, THAP, Helicobacter pylori Positive, Thyroid Adenomas, ESRB Positive, MRXS13, j372, BAF190, Primary, dtk1, Cell, DRET, xfgfr2, Evi9, Positive Finding, AA409584, Have, GNA11 Gene Mutation, KIT ligand receptor activity, Neoplasm, dRet, Replicate, background, Hepatocyte Growth Factor Receptor Gene Amplification, Detail, Destination, Pharmaceutic Preparations, HBcAb Positive, Machinery, DFR1/DFGF-R2, Tumor Protein p53 Gene Mutation, Cancers, IP Positive, Hepatitis B Surface Antigen Positive, CD117, Thyroid Cancers, N-RAS Mutation, FLT-2 Gene Mutation, ETS Transcription Factor ERG Gene Rearrangement, brahma, like-glycosyltransferase, Reports, Nonmedullary Thyroid, Ssm, CEK Gene Mutation, Anaplastic Thyroid Carcinomas, xkl-1, Alpha-11 Gene Mutation, Pharmaceutical Products, Chromatin Remodeler Gene Mutation, Brm, Data Analyses, Dfr1, Fibroblast Growth Factor Receptor 1 Gene Mutation, adult stage, Hepatitis C Viral RNA Positive, Significant, Mbp1, FLT-2 Gene Rearrangement, papillary thyroid cancer, JKT4 Gene Mutation, Xkl-1, AR+, KRAS Mutation, Reading Frame, brm, CD332, Thyroid, ESR-Beta Positive, Gsfsco1, Fibroblast Growth Factor Receptor 2 Gene Rearrangement, FGFR-3 Gene Rearrangement, diseases, diseases and disorders, FGF-R2, KGFR Gene Mutation, {Copies}, Gsfsco5, Summary Reports, SOW3, estrogen receptor positive, Targeting, Protein Expression, Observed, RTS, BCL11A-XL, RTT, CT39172, Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation, CHROMATIN REMODELING 2, papillary cancer of thyroid, Physical Shift, Dfr-1, 9930012E13Rik, Progress, c-Met Gene Amplification, Methodological Studies, C230098H17, PR+, FMS-Like Tyrosine Kinase 2 Gene Rearrangement, Anti-Hepatitis B Core Antibody Positive, Therapies, B7 Homolog 1 Positive, svs, Beta 1 (88kD) Gene Mutation, Malignancies, Positive, thyroid gland neoplasm, Cancer of Thyroid, TARGET, Therapy, Lower, Carcinoma, mTOR Signaling Pathway, B-RAF1, Molecular Fingerprinting, Anti-HBs Antibody Positive, TP53 Gene Mutation, thyroid papillary carcinoma, BCL11A-S, 1p/19q co-deletion, CG7223, KIT Proto-Oncogene Tyrosine Protein Kinase Positive, v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation, Metabolic Network, Positive Estrogen Receptor, BCL11A-L, Significance, HBsAb Positive, K-SAM Gene Mutation, Succinate Dehydrogenase Complex Flavoprotein Subunit A Positive, Screenings, Investigative Report, Primary Neoplasm, MDDGA6, Syt, Diseases, kl1-A, Genetic Materials, thyroid, Pharmaceutic, thyroid gland papillary carcinoma, LOWER, Succinate Dehydrogenase Complex Iron Sulfur Subunit B Positive, Adults, acetylglucosaminyltransferase-like 1A, Genetic Material, KRAS2 Gene Mutation, PTC, BCL11a-M, papillary carcinoma of thyroid gland, RAFB1, gyltl1b, Paired Domain Gene 8 Gene Rearrangement, DmelCG4943, mdc1d, Machinery Heart Murmur, common, Programmed Cell Death 1 Ligand 1 Positive, ESR2 Positive, kit, MEN2A, Presence, Hepatitis C RNA Positive, LARGE_HUMAN, MEN2B, A730011L11, TK25, Type 1, Identified, Positive Laboratory Test Result, Paired Box 8 Gene Rearrangement, LCAM Gene Mutation, E-Cadherin Gene Mutation, papillary cancer of the thyroid gland, Displacement, Cistron, DmHD-38, Proto Oncogenes, MeCp-2 protein, Arc-1 Gene Mutation, N-SAM Gene Mutation, N-SAM Gene Rearrangement, TK14, CD274 Positive, Evi9c, Evi9b, Evi9a, other disease, KRAS-2 Gene Mutation, dSmurf1, PDL1 Positive, Benign Neoplasm, NS7, Gene, Anaplastic Thyroid Carcinoma, KIT Positive, Anti-HBc Antibody Positive, Compare, TERT Promoter Mutation, KAL2 Gene Mutation, froggy, ECT1 Gene Rearrangement, p300 HAT, Aneuploidies, Anoctamin-1 Positive, FGFR-3 Gene Mutation, scfr, p300, Anti-Hepatitis B Virus Surface Antibody Positive, dBRM, DmelCG7184, HIV test positive, SCFR, Drugs, Erb-B2 Receptor Tyrosine Kinase Gene Mutation, BFGFR Gene Rearrangement, Gibson's Murmur, Glands, Genetic, akgdh, Malignancy, AW556123, Fibroblast Growth Factor Receptor 3 Gene Mutation, Cadherin 1, E-Cadherin (Epithelial) Gene Mutation, HER2/neu Gene Mutation, LARGE, BRCA1 Associated Protein 1 Gene Mutation, v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Positive, Ect1, non-neoplastic, BPFD#36, Trp53, Positive Lymph Node, d-smurf, Anaplastic Thyroid Cancers, C-H-RAS Gene Mutation, Proto-Oncogene, OGD Gene Rearrangement, KAL2 Gene Rearrangement, Known, SDH1 Positive, ER Alpha Positive, FGFR2, UCHL2 Gene Mutation, RAD54L Gene Mutation, GNA-11 Gene Mutation, Target Lesion Identification, CEK Gene Rearrangement, DPR3, 2210403E04Rik, drug, Thyroid Carcinoma, Cistrons, Loss of Chromosomes 1p/19q, ESTRR Positive, K-SAM Gene Rearrangement, glandula thyroidea, del(1p/19q), Fibroblast Growth Factor Receptor 3 Gene Rearrangement, B-raf, D130059H17, techniques, l(3)72Aa, KSAM, ESRA Positive, hSNF2a, Gain, ERBB2 Mutation, KGFRTr, ETV Family Rearrangement, Beta-Catenin Gene Mutation, GA11 Gene Mutation, Paired Box Gene 8 Gene Rearrangement, TP2 Promoter Mutation, Matched Tissues, ORAOV2 Positive, 2210412K19Rik, BAP1 Mutation, papillary carcinoma of thyroid, c-K-ras Gene Mutation, c-kit, SNF2alpha, FGFR-1 Gene Mutation, Inclusive, Additional, Mitochondrial Positive, Genome, glycosyltransferase-like protein LARGE1, Pharmaceutical PreparationfalseWhole Genome and Transcriptome Analysis of Anaplastic Thyroid Carcinoma - samplesThis dataset includes WGS & WTS alignment data generated from 1 ATC tumor, its matched peripheral blood specimen and 3 authenticated ATC cell lines, THJ-16T, THJ-21T and THJ-29T. In addition, it includes WTS data from extra 4 unique anaplastic cell lines, ACT-1, C643, HTh7 and T238.2017-07-26 15:39:26EGAD00001001321960626680454EGAC00000000011EGAS00001001214